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Abstract
We recently identified a new enhancer element (HIRE-1, HPV-Interferon Responsive Element-1) in the upstream regulatory region
(URR) of human papillomavirus (HPV) type 16. HIRE-1 is located upstream from and in close proximity to the TATA box. HIRE-1 is 1
nt shorter in its 5 sequence in comparison to a consensus IRF-1 binding site (IRF-E). Gel shift analyses clearly demonstrated that HIRE-1
is capable of binding IRF-1 in response to interferon- (IFN-) treatment. In a reporter system, HIRE-1 stimulated transcription in response
to IRF-1 or IFN from both a heterologous or the homologous (p97) promoter in a dose-dependent manner. Mutations in the core binding
sequence strongly decreased this enhancer activity. Interestingly, HIRE-1 stimulated transcription in the context of the full URR in a
cell-type-specific manner, thereby suggesting the role of other cell-type-specific factors that might counteract with its function. Thus, our
results may explain the inconsistent clinical and experimental results observed following IFN treatment of cervical lesions or cells. Also,
this new enhancer may have an important function during inflammatory responses against HPV type 16.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Human papillomaviruses (HPVs) are small DNA viruses
that have been found to be associated with cutaneous and mu-
cosal benign and malignant lesions (Shah, 1998; zur Hausen,
1996). Studies confirmed that cervical carcinomas contain
HPV type 16 in 50% of all patients (Bosch et al., 1995).
Cytokines such as TNF-, IL-1, TGF1, or interferons
(IFNs) have been shown to affect expression of several
HPV types: this could be inhibition (De Marco et al., 1991;
Johnson et al., 1999; Kyo et al., 1994; Nawa et al., 1990;
Woodworth et al., 1990, 1992, 1996) or activation (Gaiotti
et al., 2000; Kim et al., 2000; Woodworth et al., 1995,
1996). In fact, IFN treatment of patients with cervical in-
traepithelial neoplasia (CIN) led to mixed and controversial
outcomes (Gross, 1997). Similarly, IFN treatment resulted
in the differential regulation of HPV expression in various
cervical cancer cell lines (Kim et al., 2000). IFNs initiate a
series of phosphorylation events through the JAK/STAT
signaling pathway, leading to activation of transcription
factors such as STATs and IRF-1 (Darnell et al., 1994;
Stark et al., 1998). STAT-containing complexes bind GAS
(Decker et al., 1997) or IFN-stimulated response element
(ISRE) (Levy, 1998) elements, while IRF-1 binds IRF-E,
and thus they regulate transcription of IFN-responsive genes
(Taniguchi et al., 1995).
HPV transcription is controlled by elements present in
the upstream regulatory region (URR) (Desaintes and De-
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meret, 1997). The early (p97) promoter is located in the 3
end of the URR, and, from this promoter, transcription of
both the E6 and E7 genes is initiated. Binding sites for a
number of cellular transcription factors that influence HPV
transcription have been identified in proximity to the early
promoter (O’Connor et al., 1995). However, our knowledge
is very limited with respect to the association of those
binding sites with interferon therapies, i.e., binding of IFN-
induced transcription factors (STATs, IRFs, etc.) to the URR.
Accordingly, our aim was to identify functional IFN-
induced, protein-binding element(s) in the URR of HPV
type 16 and to study their effects on the transcription of
HPV type 16.
Results
Search for putative IFN-induced, protein-binding sites in
the URR region of HPV type 16
We used Gene Runner v.3.0 software (Hastings Soft-
ware, Inc.) to analyze the genome of HPV type 16 for the
presence of putative ISRE/IRF-E sites. We found two se-
quences that were located in proximity to the early promoter
(Table 1) that were named HIREs (HPV Interferon-Respon-
sive Elements). These sequences were partly predicted by
Iftner (Iftner, 1990) and termed E-IRS.
Those HIRE sequences were located upstream from the
TATA box: either in close proximity to it and designated as
HIRE-1 (nt 48–57 for GAACCGAAAC) or farther from it
and designated as HIRE-2 (nt 32–42 for GTAAC-
CGAAAT). However, only HIRE-1 possesses the charac-
teristic 3 end (GAAAC), while HIRE-2 has a mismatch in
its 3 end (GAAATC) compared to the consensus sequences
(GAAAC). The 5 region of HIRE-1 is one nucleotide
shorter (GAA) than the consensus IRF-E (GAAA) se-
quence, while HIRE-2 has a nucleotide substitution in its 5
sequence (GTAA). A doublet (CC) separated those two
parts in all HIREs as in the consensus IRF-E (NN). Obvi-
ously, HIRE-1 exhibits the highest homology to the IRF-1-
binding IRF-E consensus site.
HPV16 HIRE-1 is capable of binding IFN--induced
protein(s)
Because of the closest similarity to the consensus IRF-E,
we used HIRE-1 for further analysis. Earlier we determined
that HIRE-1 is capable of binding IFN--induced proteins,
but not IFN--induced protein(s), between 3 and 36 h post-
treatment (Arany et al., 2001). Accordingly, HeLa cells
were treated with IFN- (500 U/ml) for 3 h, and nuclear
extracts were prepared. An electrophoretic mobility shift
assay (EMSA) was carried out using these nuclear extracts
and end-labeled, double-stranded oligonucleotides repre-
senting HPV 16 HIRE-1 or a consensus IRF-1 (c.IRF-1)
binding sequence. Control, untreated HeLa nuclear extract
was also used (Fig. 1, lane 2). Apparently, IFN- treatment
induced binding of a protein complex to the HIRE-1 oligo
that was similar to the binding to a consensus IRF-1 se-
quence (Fig. 1, lane 8). The specificity of this binding was
determined by cold oligonucleotide competition: a 100-fold
excess of either HIRE-1 (Fig, 1. lane 4) or a consensus
IRF-1 oligonucleotide (Fig. 1, lane 5) outcompeted the
binding. Also, 100-fold excess cold HIRE-1 was able to
outcompete the protein bound to the consensus IRF-1 oli-
gonucleotides (Fig. 1, lane 9). On the contrary, a double-
mutated HIRE-1 (1T10T) was unable to compete with
HIRE-1 for the IFN-induced protein (Fig. 1, lane 6) or was
Fig. 1. HIRE-1 from HPV type 16 binds an IFN-induced protein. HeLa
cells were treated with IFN for 3 h or left intact. Nuclear extracts were
isolated and an EMSA assay was performed using an end-labeled HIRE-1
or a consensus IRF-1 (c.IRF-1) oligonucleotide. Left arrow indicates the
position of the IFN--induced band when HIRE-1 was used as a probe. The
right arrow indicates the position of the IFN--induced band (IRF-1) when
c.IRF-1 was used as a probe. Competition experiments were performed
using a 100-fold molar excess of cold oligonucleotides (Comp.) as listed.
Lanes: 1 and 7, free probes; 2, untreated HeLa nuclear extract; 3–8,
IFN--treated HeLa nuclear extracts.
Table 1
Putative ISRE/IRF-E sequences in the promoter region of HPV type 16
ISRE GNGAAA.NN.GAAACT
E-IRSa GNNRRAA.NN.GAAACY
IRF-E GAAA.CC.GAAAC/G
HIRE-1 GTTG-AA.CC.GAAACC
HIRE-2 GCGTAA.CC.GAAATC
a R  A or G; Y  C or T (Iftner, 1990).
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unable to bind it (data not shown). Also, HIRE-2 did not
bind any IFN--induced protein (data not shown). It is
interesting to note that nuclear extracts obtained from IFN-
-treated A431, CX, or SiHa cells also showed the similar
HIRE-1 binding pattern (Arany et al., 2001).
HIRE-1 binds IRF-1
We performed supershift assays to identify the nature of
binding proteins in the complex that bound to the HIRE-1
after IFN- treatment (Fig. 2.). The IFN--inducible band
was supershifted/disrupted only by an anti-IRF-1 antibody,
but not with antibodies against IRF-2, STAT1, STAT2, or
ISGF3 (p48).
IRF-1 induces transcription from the p97 or a
heterologous promoter in a dose-dependent fashion
HeLa cells were cotransfected with a pSEAP–plasmid
that contains a short segment of the URR from HPV type 16
fused to the SEAP reporter gene (pSEAP16sURR) plus an
IRF-1 expression plasmid. This short segment spans a 96-bp
fragment (nt 7–103) of the URR; it contains the TATA box,
two E2Bs overlapping with 16HIRE-1, and the Sp1 binding
site. Vector-transfected controls (SEAP-B) were also used.
At 48 h after transfection the supernatants were analyzed for
the presence of SEAP by a chemiluminescent method. As
seen in Fig. 3A, IRF-1 significantly increased amounts of
SEAP. In addition, cells were transiently cotransfected with
a plasmid that contains three tandem repeats of HPV 16
HIRE-1 in front of enhancerless SV40 promoter fused to the
SEAP reporter gene (wild type, pSEAP16–3xHIREwt, or
mutant, pSEAP16–3xHIREmt) and an IRF-1 expression
plasmid. At 48 h after transfection the supernatants were
analyzed for the presence of SEAP. The amounts of SEAP
significantly increased in the presence of the wild type, but
not the mutant, 3XHIRE-1, when IRF-1 was cotransfected.
These results suggested that HIRE-1 from HPV type 16 is a
functional enhancer element that stimulates transcription
both from the homologous (p97) promoter or from a heter-
ologous promoter in response to IRF-1.
In another set of experiments, cells were transiently co-
transfected with 2 g of pSEAP16sURR (sURR) plasmid
plus various amounts of IRF-1 expression plasmid, as indi-
cated. SEAP activity was determined 48 h after transfection.
Results are summarized in Fig. 4A. Apparently, SEAP
Fig. 3. IRF-1 induces reporter gene expression from the HPV early pro-
moter or from a heterologous promoter. (A) HeLa cells were cotransfected
with an IRF-1 or IRF-2 expression vector plus pSEAP16sURR (sURR) that
contained the minimal promoter region of the HPV16 URR fused to the
SEAP reporter gene. SEAP activity was monitored 48 h after transfection.
Measurements also included transfection with the SEAP–Basic (SEAP-B)
vector only. Transfections were done in triplicate. Values are given as
median SEAP activities  SEM. SEAP amounts were normalized to -gal
activity (see Materials and Methods). (B) HeLa cells were cotransfected
with an IRF-1 expression vector plus a plasmid (pSEAP16–3HIREwt or
pSEAP16–3HIREmt) that contained three copies of either the wild type
(wt) or mutant (mt) HIRE-1 placed in front of an SV40 promoter and the
SEAP reporter gene. SEAP activity was monitored 48 h after transfection.
Transfections were done in triplicate. Values are given as median SEAP
amounts per milliliter  SEM. SEAP amounts were normalized to -gal
activity (see Materials and Methods).
Fig. 2. IRF-1 binds HIRE-1. EMSA was performed using HIRE-1 probe
and nuclear extracts from IFN--treated HeLa cells. Supershift experi-
ments were performed using antibodies directed against IRF-1, IRF-2,
STAT1, STAT2, and ISGF3 (p48). Lanes: 1, free probe; 2–6, IFN--
treated HeLa nuclear extracts.
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amounts proportionally increased with the amounts of trans-
fected IRF-1 plasmid. Similar responses were seen using the
pSEAP16–3xHIREwt plasmid (Fig. 4B).
IRF-1 or IFN- increases the activity of the short URR in
various cervical carcinoma cell lines
We transiently cotransfected several HPV-positive
(HeLa, SiHa, CaSki and C4-II) and HPV-negative (A431,
C33 and CX) cervical carcinoma cell lines with the short
URR (pSEAP16sURR) plasmid plus an IRF-1 expression
plasmid or with the pSEAP16sURR and treated the cell
lines with IFN- for 48 h. SEAP activities were determined
as described earlier. Results are shown in Fig. 5A and are
given as fold changes compared to the vector-transfected
values. Apparently, both IRF-1 and IFN- stimulated tran-
scription from the short URR in all the cell lines we tested.
IRF-1 or IFN- affects the activity of the full URR in a
cell-type-dependent manner in various cervical carcinoma
cell lines
On the contrary, there were mixed results using the full
URR in a similar setting (Fig. 5B). Transcription was in-
creased in some cells (SiHa, A431, and C33A), but was
unchanged (HeLa and C-4II) or even decreased (CX and
CaSki) in the others. Apparently, this phenomenon did not
reflect the presence or absence of endogenous HPV.
Discussion
Cytokines induce a variety of transcription factors in the
target cells that play a role in their antiviral, antiprolifera-
tive, or immune modulatory activities. IFNs induce IFN-
responsive genes such as IRFs (Nguyen et al., 1997; Tan-
iguchi et al., 1997) through the JAK/STAT signaling
pathway (Stark et al., 1998). IRF-1 serves as a transcription
factor in mediating antiproliferative and antiviral activities
of various cytokines (Taniguchi et al., 1995) and binds to a
motif in the promoter of target genes, termed IRF-E, that
has been determined to be GAAANNGAAAC (Taniguchi et
al., 1997). IRF-1 also can bind to an element called IFN-
stimulated response element (ISRE), which is composed of
direct repeats of the sequence GAAA spaced by two nucle-
otides (Levy, 1998). A common consensus for this sequence
is GNGAAANNGAAACT (Taniguchi et al., 1997).
Our computer-assisted search identified two motifs in the
URR of HPV type 16 that resembled IRF-E and/or ISRE
elements (Table 1). Earlier, the existence of an ISRE-like
element was suggested in the URR of several HPV types
(Iftner, 1990). These sequences are located in close prox-
imity to the early promoter (p97) and overlapped two E2Bs
sites. The type found in the URR of HPV type 16 (HIRE-1,
Fig. 5. Effects of IRF-1 or IFN- on the URR reporter gene activities in
different cervical carcinoma cells. (A) Various (HPV-positive or -negative)
cervical carcinoma cells were cotransfected with pSEAP16sURR and
IRF-1 or pSEAP16sURR and treated with 500 U/ml IFN. SEAP amounts
were detected 48 h after transfection, and values are given as fold changes
compared to the vector-transfected and untreated controls (mean  SD, n
 3). (B) Various (HPV-positive or -negative) cervical carcinoma cells
were cotransfected with pSEAP16fURR and IRF-1 or pSEAP16fURR and
treated with 500 U/ml IFN. SEAP amounts were detected 48 h after
transfection and values are given as fold changes compared to the vector-
transfected and untreated controls (mean  SD, n  3).
Fig. 4. IRF-1 induces SEAP activity in a dose-dependent fashion. HeLa cells
were co-transfected with 2 g of pSEAP16sURR (sURR) or pSEAP16–
3HIRE (wt or mt) plus indicated amounts of IRF-1 expression vector. SEAP
activity was monitored 48 hours after transfection. Transfections were done in
triplicate. Values are given as median SEAP amounts/ml.
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GAACCGAAAC) is closely homologous to the consensus
IRF-E (GAAANNGAAAC) element (Table 1).
Closer analysis of HIRE-1 revealed that it binds IFN--
induced proteins in an inducible manner (Fig. 1.). Compe-
tition experiments demonstrated the specificity of this bind-
ing (Fig. 1). Mutations in this element abolished its
competition for IRF-1 binding (Fig. 1, lane 6) and stimula-
tion of the reporter gene in response to IRF-1 (Fig. 3A) or
IFN- (Fig. 5).
The 5 consensus-like sequence in HIRE-1 is a nucleo-
tide shorter (GAA) than the consensus (GAAA) IRF-E, but
it did not weaken the IRF-1 binding affinity of HIRE-1 (Fig.
1, lane 3) compared to the consensus sequence (Fig. 1, lane
8). Also, HIRE-1 was found to be a strong competitor to the
consensus IRF-1 binding sequence as well (Fig. 1, lane 9).
Transient transfection experiments demonstrated that the
HIRE-1 is a functional enhancer: it was able to stimulate
transcription from the homologous (p97) and a heterologous
promoter in response to IRF-1 or IFN- (Fig. 3 and Fig. 5A)
in a dose-dependent manner (Fig. 4).
Interestingly, in the context of the full URR IRF-1,
transfection or IFN treatment stimulated transcription from
the p97 promoter in a cell-type-specific fashion (Fig. 5B)
even though binding of IRF-1 to HIRE-1 didn’t show this
specificity (Arany et al., 2001). These results suggest that
cell-type-specific factors that are related to IFN- or IRF-1
stimuli might counteract with the HIRE-1 stimulation.
These observations are in agreement with those that de-
scribed cell-type-specific silencing of HPV transcription
(Sailaja et al., 1999). It is also known that the effects of
IFNs on HPV early mRNA levels are highly diverse or even
contradictory (Gross, 1997; Kim et al., 2000); therefore,
cell-type specificity or status of the IFN-signaling pathway
should be revisited.
In light of these facts, the exact role of HIRE in the
regulation of HPV transcription remains partly unresolved.
One can speculate that HIRE might function by influencing
the overlapping E2 sites. Those E2 sites repress transcrip-
tion from the HPV promoter, and thus, IRF-1-binding to the
overlapping HIREs could be competitive or synergistic. It is
tempting to hypothesize that HIRE might participate in the
early phase of abolishment of immune surveillance by in-
creasing E7 levels in response to inflammatory cytokines
secreted by immune cells and thus might help to escape
from immune surveillance. Either way, HIRE is a newly dis-
covered enhancer element in the URR of HPV 16, which might
be an important part of IFN responses during inflammation.
Materials and methods
Cell culture
HeLa, CaSki, SiHa, C-4II, A431, and C33A cells were
purchased from ATCC and grown at 37°C in DMEM sup-
plemented with 10% FCS and 100 g/ml penicillin plus 100
U/ml streptomycin, in 5% CO2 atmosphere. The HPV-
negative CX cervical carcinoma cell line was a gift from Dr.
Chen (Chou et al., 1996).
Plasmid construction
The minimal promoter region of HPV type 16 (nt 7–103)
was inserted into a pSEAP2–Basic plasmid (pSEAP16sURR)
as described earlier (Arany et al., 2002a). In a similar way
a 1060-bp fragment of the HPV16 genome (between nt
7050 and 103) spanning the full URR plus the early pro-
moter was constructed (pSEAP16fURR). The HPV16 ge-
nome was a gift from Dr. Teh-sheng Chan (Department of
Microbiology and Immunology, UTMB, Galveston, TX).
The pSEAP16–3xHIREwt recombinant plasmid was
constructed by annealing three copies of the wild type HPV
16 HIRE-1 (5-GTTGAACCGAAAC-3) with linker se-
quences (5-KpnI, GGTACC, and 3-BglII, AGATCT) into
a pSEAP2–promoter plasmid (Clontech, Palo Alto, CA).
The pSEAP16–3xHIREmt was constructed by annealing
three copies of the mutated HPV 16 HIRE-1 (5-GTTTA-
ACCGAAAT-3) with similar linker sequences into a
pSEAP2–promoter plasmid (Clontech, Palo Alto, CA).
Construction of the IRF-1 expression vector was de-
scribed earlier (Arany et al., 2002a). The IRF-1 cDNA was
a gift from Dr. Taniguchi (Department of Immunology,
Graduate School of Medicine and Faculty of Medicine,
University of Tokyo, Japan).
Electrophoretic mobility shift assay
Nuclear extracts were prepared by lysing cells in a buffer
containing 10 mM Hepes, pH 7.9, 60 mM KCl, 1 mM DTT,
1 mM EDTA, 0.5% NP-40, and 1 mM PMSF. Five to ten
micrograms of nuclear extracts was incubated in a binding
buffer (10 mM Tris–HCl, pH 7.6, 50 mM KCl, 5 mM
MgCl2, 0.1 mM EDTA, 6% glycerol, 1 mM DTT, and 1 g
polydIC) in the presence or absence of a 100-fold molar
excess of unlabeled competitor DNA and/or appropriate
antibodies on ice for 10 min. Following incubation, 10,000
cpm of 32P end-labeled oligonucleotide probe was added
and the reaction incubated at room temperature for an ad-
ditional 30 min. The DNA–protein complexes were sepa-
rated from the free probe by electrophoresis on a 6% poly-
acrylamide gel. The gel was dried and subjected to
autoradiography. Oligonucleotides were custom designed
and synthesized (Bio-Synthesis, Inc., Denton, TX). Anneal-
ing of individual oligos was done according to standard
protocols.
Gel-shift oligonucleotides
For gel-shift competitions, oligonucleotides were synthe-
sized by Bio-Sysnthesis, Inc. (Denton, TX), and were an-
nealed according to a standard protocol. These oligos are
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listed below. The putative core binding sequence is under-
lined; mutated bases are in bold (the sense strand is shown):
HPV16 HIRE-1 ATCGGTTGAACCGAAACCGG
1T10T HIRE-1 mutant ATCGGTTTAACCGAAATCGG
The consensus IRF-1 gel-shift oligonucleotide (GGAA-
GCGAAAATGAAATTGACT) was purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA).
Plasmid transfection
HeLa cells were transfected with the above described or
control plasmids using GenePORTER 2 transfection reagent
(GTS Inc., San Diego, CA) as reported earlier (Arany et al.,
2002a, 2002b). Aliquots of the supernatants (100 l) were
removed at various time points (24 and 48 h, respectively)
and kept at 70°C until SEAP activity was measured.
Measurement of SEAP reporter activity
The pSEAP2 plasmids (Clontech) used SEAP (a secreted
form of human placental alkaline phosphatase) as a reporter
gene. Aliquots of 100 l from the supernatants were re-
moved and used for SEAP determinations (Arany et al.,
2002a, 2002b).
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